Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

Goldman Sachs initiated coverage of ResMed (RMD) with a Buy rating and A$48.90 price target The firm says its Buy thesis is based on “robust” ...

The stock's rise snapped a four-day losing streak.

The investing pros at Firetrail forecast another strong year for ResMed shares in 2025. The post ResMed shares are up 42% in ...

Signal Advisors Wealth LLC increased its stake in ResMed Inc. (NYSE:RMD – Free Report) by 6.1% in the 4th quarter, according ...

Shares of ResMed Inc. RMD slumped 0.62% to $228.83 Tuesday, on what proved to be an all-around favorable trading session for ...

Chipotle Mexican Grill owns and operates Chipotle Mexican Grill restaurants. The company’s expected earnings growth rate for ...

Fintel reports that on January 10, 2025, Piper Sandler initiated coverage of ResMed (NYSE:RMD) with a Neutral recommendation.

OSA impacts about 936 million people worldwide and occurs when the throat muscles relax and block the airway with a common ...

Shares of ResMed Inc. (NYSE:RMD – Get Free Report) have earned a consensus rating of “Hold” from the thirteen brokerages that are currently covering the firm, MarketBeat Ratings reports. One analyst ...

Adam Maeder, an analyst from Piper Sandler, has initiated a new Hold rating on Resmed (RMD).Stay Ahead of the Market:Discover outperforming ...